Back to Cancer Australia's website
This guideline is based on one meta-analysis2 about the use of taxane-containing regimens for adjuvant treatment of early breast cancer and a NBOCC* systematic review3 about taxane-containing regimens for neoadjuvant treatment of early breast cancer.
* In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.
The statements and recommendations about taxanes for adjuvant treatment of early breast cancer are based on a Cochrane review and meta-analysis,2 which includes available evidence from twelve randomised trials4–15 assessing the adjuvant use of taxanes in early (operable) breast cancer. The trials compared taxane-containing adjuvant chemotherapy regimens with adjuvant regimens not containing a taxane in the management of women with early (operable) breast cancer. Both pre-menopausal and post-menopausal women were eligible in all trials. Five of the twelve trials used paclitaxel.4,8-11 The remaining seven trials used docetaxel.5-7,12-15
The statements about taxanes for neoadjuvant treatment of early breast cancer are based on evidence from a NBOCC* systematic review3 of eight randomised trials16–23 assessing the neoadjuvant use of taxanes for early (operable) breast cancer.
(see table 3 for trial details)
* In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.
Prev
Up
Next